loading
Arrowhead Pharmaceuticals Inc stock is traded at $18.39, with a volume of 90,256. It is down -1.54% in the last 24 hours and down -10.10% over the past month. Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
See More
Previous Close:
$18.71
Open:
$18.75
24h Volume:
90,256
Relative Volume:
0.09
Market Cap:
$2.32B
Revenue:
$181.74M
Net Income/Loss:
$-296.81M
P/E Ratio:
-10.75
EPS:
-1.71
Net Cash Flow:
$-402.70M
1W Performance:
-13.96%
1M Performance:
-10.10%
6M Performance:
-26.37%
1Y Performance:
-35.07%
1-Day Range:
Value
$18.21
$18.79
1-Week Range:
Value
$18.03
$21.25
52-Week Range:
Value
$17.05
$39.83

Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile

Name
Name
Arrowhead Pharmaceuticals Inc
Name
Phone
626-696-4702
Name
Address
177 E COLORADO BLVD, PASADENA, CA
Name
Employee
525
Name
Next Earnings Date
2024-11-27
Name
Latest SEC Filings
Name
ARWR's Discussions on Twitter

Compare ARWR with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
ARWR 18.36 2.32B 181.74M -296.81M -402.70M -1.71
VRTX 447.62 115.74B 10.63B -479.80M -1.35B 13.33
REGN 741.31 81.65B 13.85B 4.65B 3.32B 35.06
ARGX 590.40 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 248.88 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 103.29 24.49B 3.30B -501.07M 1.03B 11.54

Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades

Date Action Analyst Rating Change
Dec-04-23 Initiated BofA Securities Buy
Sep-19-23 Initiated Citigroup Neutral
Jul-21-23 Initiated TD Cowen Outperform
May-12-23 Downgrade SVB Securities Outperform → Market Perform
Apr-26-23 Initiated SMBC Nikko Outperform
Apr-12-23 Upgrade SVB Securities Market Perform → Outperform
Mar-21-23 Initiated Bernstein Mkt Perform
Sep-09-22 Initiated Morgan Stanley Equal-Weight
May-11-22 Upgrade Robert W. Baird Neutral → Outperform
Jan-19-22 Resumed Goldman Buy
Aug-06-21 Reiterated Chardan Capital Markets Buy
Jun-04-21 Resumed Robert W. Baird Neutral
Feb-05-21 Reiterated H.C. Wainwright Buy
Dec-21-20 Downgrade Robert W. Baird Outperform → Neutral
Dec-16-20 Initiated UBS Buy
Nov-19-20 Initiated Citigroup Buy
May-13-20 Initiated RBC Capital Mkts Outperform
May-08-20 Upgrade Oppenheimer Perform → Outperform
Apr-15-20 Upgrade Cantor Fitzgerald Neutral → Overweight
Mar-24-20 Upgrade SVB Leerink Underperform → Mkt Perform
Mar-17-20 Initiated Goldman Neutral
Jan-21-20 Initiated SVB Leerink Underperform
Dec-13-19 Initiated Oppenheimer Perform
Nov-29-19 Reiterated Chardan Capital Markets Buy
Nov-27-19 Reiterated B. Riley FBR Buy
Nov-25-19 Upgrade Robert W. Baird Neutral → Outperform
Oct-24-19 Downgrade Robert W. Baird Outperform → Neutral
Oct-22-19 Reiterated Chardan Capital Markets Buy
Oct-03-19 Initiated Robert W. Baird Outperform
Sep-07-18 Upgrade B. Riley FBR Neutral → Buy
Sep-06-18 Reiterated Chardan Capital Markets Buy
Aug-08-18 Reiterated Cantor Fitzgerald Overweight
Jul-02-18 Reiterated Chardan Capital Markets Buy
View All

Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News

pulisher
03:11 AM

Principal Financial Group Inc. Has $5.64 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

03:11 AM
pulisher
Nov 19, 2024

Familial Chylomicronemia Syndrome Market Expected to Experience Major Growth by 2034, According to DelveInsight | Ionis Pharma, Novartis, Akcea Therapeutics, Arrowhead Pharma, Visirna Therapeutics - Barchart

Nov 19, 2024
pulisher
Nov 19, 2024

Familial Chylomicronemia Syndrome Market Expected - openPR

Nov 19, 2024
pulisher
Nov 19, 2024

Arrowhead Pharmaceuticals (ARWR) to Release Quarterly Earnings on Tuesday - MarketBeat

Nov 19, 2024
pulisher
Nov 18, 2024

Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - BioSpace

Nov 18, 2024
pulisher
Nov 18, 2024

Arrowhead seeks FDA nod for rare disease drug - Investing.com

Nov 18, 2024
pulisher
Nov 18, 2024

Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire

Nov 18, 2024
pulisher
Nov 15, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Shares Down 6.3%Here's What Happened - MarketBeat

Nov 15, 2024
pulisher
Nov 10, 2024

When (ARWR) Moves Investors should Listen - Stock Traders Daily

Nov 10, 2024
pulisher
Nov 10, 2024

Privium Fund Management B.V. Has $6.46 Million Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Nov 10, 2024
pulisher
Nov 08, 2024

Leerink Partnrs Has Positive Outlook of ARWR FY2024 Earnings - MarketBeat

Nov 08, 2024
pulisher
Nov 06, 2024

Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - BioSpace

Nov 06, 2024
pulisher
Nov 04, 2024

Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - BioSpace

Nov 04, 2024
pulisher
Nov 04, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - BioSpace

Nov 04, 2024
pulisher
Nov 03, 2024

abrdn plc Has $7.77 Million Stock Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Nov 03, 2024
pulisher
Nov 01, 2024

Arrowhead Launches FCS Awareness Campaign - Baystreet.ca

Nov 01, 2024
pulisher
Nov 01, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, 'We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Quantisnow

Nov 01, 2024
pulisher
Nov 01, 2024

Arrowhead Pharmaceuticals Launches New Disease Awareness Campaig - GuruFocus.com

Nov 01, 2024
pulisher
Nov 01, 2024

In the wake of Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest US$108m market cap drop, institutional owners may be forced to take severe actions - Simply Wall St

Nov 01, 2024
pulisher
Oct 31, 2024

International Assets Investment Management LLC Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 31, 2024
pulisher
Oct 30, 2024

(ARWR) Long Term Investment Analysis - Stock Traders Daily

Oct 30, 2024
pulisher
Oct 30, 2024

Assenagon Asset Management S.A. Has $5.68 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 30, 2024
pulisher
Oct 28, 2024

Analysts Set Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Target Price at $45.33 - MarketBeat

Oct 28, 2024
pulisher
Oct 21, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 6.4%Here's Why - MarketBeat

Oct 21, 2024
pulisher
Oct 20, 2024

(ARWR) Trading Signals - Stock Traders Daily

Oct 20, 2024
pulisher
Oct 18, 2024

Buffington Mohr McNeal Takes Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 18, 2024
pulisher
Oct 17, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Upgraded at StockNews.com - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

State Street Corp's Strategic Acquisition in Arrowhead Pharmaceu - GuruFocus.com

Oct 16, 2024
pulisher
Oct 16, 2024

80+ Pharma Companies Unite to Shape the Future of RNA-Based Therapeutics | DelveInsight - GlobeNewswire

Oct 16, 2024
pulisher
Oct 15, 2024

Alpha-1 Antitrypsin Deficiency Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, MOA, ROA by DelveInsight | Apic Bio, Dicerna Pharma, Peak Bio, Arrowhead Pharma - The Globe and Mail

Oct 15, 2024
pulisher
Oct 15, 2024

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)October 14, 2024 - BioSpace

Oct 15, 2024
pulisher
Oct 11, 2024

HC Wainwright Reiterates Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat

Oct 11, 2024
pulisher
Oct 11, 2024

Arrowhead Pharmaceuticals (STU:HDP1) EV-to-Revenue : 93.89 (As of Oct. 11, 2024) - GuruFocus.com

Oct 11, 2024
pulisher
Oct 10, 2024

Dimensional Fund Advisors LP Boosts Holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highlights: Navigating Financial ... - Yahoo Finance

Oct 09, 2024
pulisher
Oct 09, 2024

Arrowhead Pharmaceuticals Inc (ARWR) Q3 2024 Earnings Call Highl - GuruFocus.com

Oct 09, 2024
pulisher
Oct 09, 2024

Arrowhead Pharmaceuticals Plans $250M Manufacturing Plant in Wisconsin - Pasadena Now

Oct 09, 2024
pulisher
Oct 09, 2024

How to Take Advantage of moves in (ARWR) - Stock Traders Daily

Oct 09, 2024
pulisher
Oct 08, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Given Overweight Rating at Piper Sandler - MarketBeat

Oct 08, 2024
pulisher
Oct 08, 2024

Goldman Sachs holds Neutral rating on Arrowhead stock By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 08, 2024

Arrowhead Pharma maintains Buy rating from TD Cowen after R&D day insights - Investing.com Canada

Oct 08, 2024
pulisher
Oct 08, 2024

Arrowhead Pharma retains Overweight rating from Piper Sandler By Investing.com - Investing.com Canada

Oct 08, 2024
pulisher
Oct 07, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Hits New 1-Year LowShould You Sell? - MarketBeat

Oct 07, 2024
pulisher
Oct 07, 2024

ARWR stock touches 52-week low at $18.14 amid market challenges - Investing.com Canada

Oct 07, 2024
pulisher
Oct 07, 2024

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Acquired by Millennium Management LLC - MarketBeat

Oct 07, 2024
pulisher
Oct 06, 2024

Bank of Montreal Can Buys 30,866 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - MarketBeat

Oct 06, 2024
pulisher
Oct 04, 2024

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment? - Simply Wall St

Oct 04, 2024
pulisher
Oct 03, 2024

Arrowhead: A First Approval LikelyJury Still Out On Investment Opportunity (ARWR) - Seeking Alpha

Oct 03, 2024
pulisher
Oct 03, 2024

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat

Oct 03, 2024
pulisher
Oct 01, 2024

Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year Low at $18.61 - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Severe Hypertriglyceridemia Market Growth to Accelerate - openPR

Sep 30, 2024

Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Arrowhead Pharmaceuticals Inc Stock (ARWR) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Vakiener Victoria
Director
May 02 '24
Sale
23.31
1,799
41,935
30,205
Hamilton James C
Chief Discovery/Trans Medicine
Apr 01 '24
Sale
28.03
6,000
168,180
204,851
Lu Hongbo
Director
Mar 19 '24
Buy
28.00
1,000
28,000
32,680
Lu Hongbo
Director
Mar 20 '24
Buy
27.50
1,000
27,500
33,680
Lu Hongbo
Director
Mar 18 '24
Buy
27.49
1,000
27,490
31,680
Myszkowski Kenneth Allen
Chief Financial Officer
Mar 06 '24
Sale
35.19
40,000
1,407,600
400,600
Anzalone Christopher Richard
Chief Executive Officer
Jan 31 '24
Option Exercise
14.54
57,499
836,035
3,772,547
Anzalone Christopher Richard
Chief Executive Officer
Jan 31 '24
Sale
32.35
57,499
1,860,019
3,715,048
Hamilton James C
Chief Discovery/Trans Medicine
Jan 12 '24
Sale
36.89
7,940
292,904
210,851
GIVEN DOUGLAS B
Director
Jan 11 '24
Sale
38.06
2,911
110,788
129,711
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):